{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:08:08Z","timestamp":1768216088246,"version":"3.49.0"},"reference-count":61,"publisher":"Index Copernicus","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Otolaryngol Pol"],"published-print":{"date-parts":[[2025,12,14]]},"abstract":"<ns3:p>Laryngopharyngeal reflux disease (LPRD) is an entity separate from GERD in which the refluxate (acid, pepsin, bile salts, etc.) crosses the upper esophageal sphincter and irritates the particularly sensitive pharyngeal and laryngeal mucosa, resulting in symptoms such as hoarseness, coughing, and grunting, frequently without the typical heartburn or esophageal erosions. The diagnosis cannot rely solely on the laryngoscopic appearance or the RSI\/RFS scales (Reflux Symptom Index\/Reflux Finding Score). The reference standard is hypopharyngeal\u2013esophageal multichannel intraluminal impedance with pH monitoring (HEMII-pH), which documents the extent of reflux (acidic, non-acidic, gaseous) reaching the pharynx and allows for LPRD phenotyping and treatment selection. Gastroscopy is reserved mainly for alarm symptoms and complications of GERD. The treatment should be personalized and multidirectional, including lifestyle and diet modification as well as pharmacotherapy targeting the type of reflux. In weak acid\/non-acid reflux, an important part is played by alginates (exerting mechanical action within the stomach to reduce postprandial and nocturnal reflux) and topical barrier preparations with hyaluronic acid that form a bioadhesive protective film on the mucosa and promote its regeneration. Prokinetic agents should be considered, especially in patients with motility disorders or distal reflux. Proton pump inhibitors should be used selectively, mainly with documented acid exposure or concomitant typical GERD symptoms. Effective care requires collaboration between an otolaryngologist and a gastroenterologist, with diagnostic and therapeutic decisions being based on the phenotype of reflux as well as the patient\u2019s preferences. This personalized approach reduces the risk of over-suppression of gastric acid and increases the clinical response rate.<\/ns3:p>","DOI":"10.5604\/01.3001.0055.5225","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T10:45:26Z","timestamp":1767005126000},"page":"42-54","source":"Crossref","is-referenced-by-count":0,"title":["Laryngopharyngeal reflux: a diagnostic and therapeutic challenge for the otolaryngologist and gastroenterologist"],"prefix":"10.5604","volume":"79","author":[{"given":"Wioletta","family":"Pietruszewska","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Oncology, Medical University of Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-3128","authenticated-orcid":false,"given":"Maria","family":"Janiak","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Medical University of Gdansk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena M.","family":"Pietrzak","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Oncology, Medical University of Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3689","reference":[{"key":"634891r1","doi-asserted-by":"crossref","unstructured":"\u015awidnicka-Siergiejko A.K., Marek T., Wa\u015bko-Czopnik D. et al.: Diagnostic andtherapeutic management in gastroesophageal reflux disease: Consensus of thePolish Society of Gastroenterology. Polish Arch Intern Med., 2022; 132(2): 16196 doi: 10.20452\/PAMW.16196.","DOI":"10.20452\/pamw.16196"},{"key":"634891r2","doi-asserted-by":"crossref","unstructured":"Chen J.W., Vela M.F., Peterson K.A., Carlson D.A.: AGA Clinical Practice Updateon the Diagnosis and Management of Extraesophageal Gastroesophageal RefluxDisease: Expert Review. Clin Gastroenterol Hepatol., 2023; 21: 1414\u20131421.e3.doi: 10.1016\/j.cgh.2023.01.040.","DOI":"10.1016\/j.cgh.2023.01.040"},{"key":"634891r3","unstructured":"Wa\u015bko-Czopnik D., G\u0105siorowska A., Janiak M. et al.: Rekomendacje dla lekarzy rodzinnych dotycz\u0105ce diagnostyki i leczenia choroby refluksowej prze\u0142yku.Lek POZ., 2024; 10 (4): 190\u2013201."},{"key":"634891r4","doi-asserted-by":"crossref","unstructured":"Vakil N., Van Zanten S. V., Kahrilas P. et al.: The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am JGastroenterol., 2006; 101(8): 1900\u20131920. doi: 10.1111\/J.1572-0241.2006.00630.X.","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"634891r5","doi-asserted-by":"crossref","unstructured":"Koufman J.A., Aviv J.E., Casiano R.R., Shaw G.Y.: Laryngopharyngeal reflux:position statement of the committee on speech, voice, and swallowing disordersof the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg., 2002; 127: 32\u201335. doi: 10.1067\/MHN.2002.125760.","DOI":"10.1067\/mhn.2002.125760"},{"key":"634891r6","doi-asserted-by":"crossref","unstructured":"Lechien J.R., Chiesa-Estomba C.M., Hans S. et al.: European clinical practice guideline: managing and treating laryngopharyngeal reflux disease. Eur Arch Oto-Rhino-Laryngology., 2024. Online ahead of print. doi: 10.1007\/s00405-024-09181-z.","DOI":"10.1007\/s00405-024-09181-z"},{"key":"634891r7","doi-asserted-by":"crossref","unstructured":"Lechien J.R., Vaezi M.F., Chan W.W. et al.: The Dubai Definition and DiagnosticCriteria of Laryngopharyngeal Reflux: The IFOS Consensus. Laryngoscope.,2024; 134: 1614\u20131624. doi: 10.1002\/lary.31134.","DOI":"10.1002\/lary.31324"},{"key":"634891r8","doi-asserted-by":"crossref","unstructured":"Koufman J.A.: The otolaryngologic manifestations of gastroesophageal refluxdisease (GERD): a clinical investigation of 225 patients using ambulatory 24--hour pH monitoring and an experimental investigation of the role of acid andpepsin in the development of laryngeal injury. Laryngoscope., 1991; 101: 1\u201378.doi: 10.1002\/LARY.1991.101.S53.1.","DOI":"10.1002\/lary.1991.101.s53.1"},{"key":"634891r9","doi-asserted-by":"crossref","unstructured":"Koufman J.A., Amin M.R., Panetti M.: Prevalence of reflux in 113 consecutive patients with laryngeal and voice disorders. Otolaryngol Head Neck Surg.,2000; 123: 385\u2013388. doi: 10.1067\/MHN.2000.109935.","DOI":"10.1067\/mhn.2000.109935"},{"key":"634891r10","doi-asserted-by":"crossref","unstructured":"Lechien J.R., Akst L.M., Hamdan A.L. et al.: Evaluation and Management ofLaryngopharyngeal Reflux Disease: State of the Art Review. Otolaryngol HeadNeck Surg., 2019; 160: 762\u2013782. doi: 10.1177\/0194599819827488.","DOI":"10.1177\/0194599819827488"},{"key":"634891r11","doi-asserted-by":"crossref","unstructured":"Samuels T.L., Aoun, J., Husain, I. et al.: Advances in laryngopharyngeal reflux:Etiology, diagnosis, and management. Ann. N. Y. Acad. Sci. 2024, 53\u201362. doi:10.1111\/nyas.15242.","DOI":"10.1111\/nyas.15242"},{"key":"634891r12","doi-asserted-by":"crossref","unstructured":"Krause A.J., Yadlapati R.: Review article: Diagnosis and management of laryngopharyngeal reflux. Aliment Pharmacol Ther., 2024; 59: 616\u2013631. doi:10.1111\/apt.17858.","DOI":"10.1111\/apt.17858"},{"key":"634891r13","doi-asserted-by":"crossref","unstructured":"Lechien J.R., Geneid A., Bohlender J.E. et al.: Consensus for voice quality assessment in clinical practice: guidelines of the European Laryngological Societyand Union of the European Phoniatricians. Eur Arch Oto-Rhino-Laryngology., 2023; 280: 5459\u20135473. doi: 10.1007\/S00405-023-08211-6.","DOI":"10.1007\/s00405-023-08211-6"},{"key":"634891r14","doi-asserted-by":"crossref","unstructured":"Becker V., Drabner R., Graf S. et al.: New aspects in the pathomechanism anddiagnosis of the laryngopharyngeal reflux-clinical impact of laryngeal protonpumps and pharyngeal pH metry in extraesophageal gastroesophageal refluxdisease. World J Gastroenterol., 2015; 21: 982\u2013987. doi: 10.3748\/WJG.V21.I3.982.","DOI":"10.3748\/wjg.v21.i3.982"},{"key":"634891r15","doi-asserted-by":"crossref","unstructured":"Eckley C.A., Costa H.O.: Comparative study of salivary pH and volume inadults with chronic laryngopharyngitis by gastroesophageal reflux diseasebefore and after treatment. Braz J Otorhinolaryngol., 2006; 72: 55\u201360. doi:10.1016\/S1808-8694(15)30035-5.","DOI":"10.1016\/S1808-8694(15)30035-5"},{"key":"634891r16","doi-asserted-by":"crossref","unstructured":"Lechien J.R.: Minimum Effective Duration of Laryngopharyngeal Reflux Disease Treatment: A Prospective Study. Otolaryngol Head Neck Surg., 2024;171(4): 1114\u20131122. doi: 10.1002\/ohn.878.","DOI":"10.1002\/ohn.878"},{"key":"634891r17","doi-asserted-by":"crossref","unstructured":"Barry D.W., Vaezi M.F.: Laryngopharyngeal reflux: More questions than answers. Cleve Clin J Med., 2010; 77: 327\u2013334. doi: 10.3949\/CCJM.77A.09121.","DOI":"10.3949\/ccjm.77a.09121"},{"key":"634891r18","doi-asserted-by":"crossref","unstructured":"Guan Y., Cheng H., Zhang N. et al.: The role of the esophageal and intestinalmicrobiome in gastroesophageal reflux disease: past, present, and future. FrontImmunol., 2025; 16: 1558414. doi: 10.3389\/FIMMU.2025.1558414.","DOI":"10.3389\/fimmu.2025.1558414"},{"key":"634891r19","doi-asserted-by":"crossref","unstructured":"Sugihartono T., Fauzia K.A., Miftahussurur M. et al.: Analysis of gastric microbiota and Helicobacter pylori infection in gastroesophageal reflux disease.Gut Pathog., 2022; 14: 1\u20139. doi: 10.1186\/S13099-022-00510-3.","DOI":"10.1186\/s13099-022-00510-3"},{"key":"634891r20","doi-asserted-by":"crossref","unstructured":"Hu Z., Shan B., Wang Y. et al.: Association of gastroesophageal reflux diseasewith small intestinal bacterial overgrowth: a case-control study. BMC Gastroenterol., 2025; 25: 753. doi: 10.1186\/S12876-025-04291-2.","DOI":"10.1186\/s12876-025-04291-2"},{"key":"634891r21","doi-asserted-by":"crossref","unstructured":"Chen H., Wang H., Yang F., Wang M., Chen X.: Distinct microbiota dysbiosis inpatients with laryngopharynx reflux disease compared to healthy controls. EurArch Otorhinolaryngol., 2022; 279: 3569\u20133579. doi: 10.1007\/S00405-022-07327-5.","DOI":"10.1007\/s00405-022-07327-5"},{"key":"634891r22","doi-asserted-by":"crossref","unstructured":"Zhang J., Fan X.: Analysis on the pharyngeal microbiota in patients with laryngopharyngeal reflux disease. Braz J Otorhinolaryngol., 2023; 89(6): 101331.doi: 10.1016\/j.bjorl.2023.101331.","DOI":"10.1016\/j.bjorl.2023.101331"},{"key":"634891r23","doi-asserted-by":"crossref","unstructured":"Cui X., Yin L., Zhang Y. et al.: Salivary microbiota composition before andafter use of proton pump inhibitors in patients with laryngopharyngeal reflux: a self-control study. BMC Oral Health., 2024, 24 (1):1194. doi: 10.1186\/S12903-024-05000-3.","DOI":"10.1186\/s12903-024-05000-3"},{"key":"634891r24","doi-asserted-by":"crossref","unstructured":"Zheng X., Zheng Y., Chen T. et al.: Effect of Laryngopharyngeal Reflux and Potassium-Competitive Acid Blocker (P-CAB) on the Microbiological Compriseof the Laryngopharynx. Otolaryngol Head Neck Surg., 2024; 170: 1380\u20131390.doi: 10.1002\/OHN.682.","DOI":"10.1002\/ohn.682"},{"key":"634891r25","doi-asserted-by":"crossref","unstructured":"Lechien J.R., Bobin F., Dapri G. et al.: Hypopharyngeal-Esophageal Impedance-pH Monitoring Profiles of Laryngopharyngeal Reflux Patients. Laryngoscope., 2021; 131: 268\u2013276. doi: 10.1002\/LARY.28736.","DOI":"10.1002\/lary.28736"},{"key":"634891r26","doi-asserted-by":"crossref","unstructured":"Lee J.G.: Microbiota, Gut Health, and Laryngopharyngeal Reflux Disease. Otolaryngol Clin North Am., 2025; 58: 433\u2013440. doi: 10.1016\/J.OTC.2024.09.006.","DOI":"10.1016\/j.otc.2024.09.006"},{"key":"634891r27","doi-asserted-by":"crossref","unstructured":"Katz P.O., Dunbar K.B., Schnoll-Sussman F.H. et al.: ACG Clinical Guidelinefor the Diagnosis and Management of Gastroesophageal Reflux Disease. AmJ Gastroenterol., 2022; 117: 27\u201356. doi: 10.14309\/AJG.0000000000001538.","DOI":"10.14309\/ajg.0000000000001538"},{"key":"634891r28","doi-asserted-by":"crossref","unstructured":"Belafsky P.C., Postma G.N., Koufman J.A.: The validity and reliability ofthe reflux finding score (RFS). Laryngoscope., 2001; 111: 1313\u20131317. doi:10.1097\/00005537-200108000-00001.","DOI":"10.1097\/00005537-200108000-00001"},{"key":"634891r29","doi-asserted-by":"crossref","unstructured":"Belafsky P.C., Postma G.N., Koufman J.A.: Validity and Reliability of the Reflux Symptom Index (RSI). J Voice., 2002; 16: 274\u2013277. doi: 10.1016\/S0892-1997(02)00097-8.","DOI":"10.1016\/S0892-1997(02)00097-8"},{"key":"634891r30","doi-asserted-by":"crossref","unstructured":"Jahshan F., Ronen O., Qarawany J. et al.: Inter-Rater Variability of Reflux FindingScore Amongst Otolaryngologists. J Voice., 2022; 36: 685\u2013689. doi: 10.1016\/J.JVOICE.2020.07.021.","DOI":"10.1016\/j.jvoice.2020.07.021"},{"key":"634891r31","doi-asserted-by":"crossref","unstructured":"Vance D., Alnouri G., Shah P. et al.: The Validity and Reliability of the RefluxFinding Score. J Voice., 2023; 37: 92\u201396. doi: 10.1016\/J.JVOICE.2020.11.008.","DOI":"10.1016\/j.jvoice.2020.11.008"},{"key":"634891r32","doi-asserted-by":"crossref","unstructured":"Lechien J.R., De Marrez L.G., Finck C., Saussez S.: Validity and Reliability of theReflux Sign Assessment-10 (RSA-10). Laryngoscope., 2024; 134: 3981\u20133988.doi: 10.1002\/lary.31420.","DOI":"10.1002\/lary.31420"},{"key":"634891r33","doi-asserted-by":"crossref","unstructured":"Popek B., Bojanowska-Po\u017aniak K., Tomasik B. et al.: Clinical experience of narrow band imaging (NBI) usage in diagnosis of laryngeal lesions. OtolaryngolPol., 2019; 73: 18\u201323. doi: 10.5604\/01.3001.0013.3401.","DOI":"10.5604\/01.3001.0013.3401"},{"key":"634891r34","doi-asserted-by":"crossref","unstructured":"Vaezi M.F., Hicks D.M., Abelson,T.I., Richter J.E.: Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): A critical assessment ofcause and effect association. Clin Gastroenterol Hepatol., 2003; 1: 333\u2013344.doi: 10.1053\/S1542-3565(03)00177-0.","DOI":"10.1053\/S1542-3565(03)00177-0"},{"key":"634891r35","doi-asserted-by":"crossref","unstructured":"Branski R.C., Bhattacharyya N., Shapiro J.: The reliability of the assessmentof endoscopic laryngeal findings associated with laryngopharyngeal refluxdisease. Laryngoscope., 2002; 112: 1019\u20131024. doi: 10.1097\/00005537--200206000-00016.","DOI":"10.1097\/00005537-200206000-00016"},{"key":"634891r36","doi-asserted-by":"crossref","unstructured":"Pillutla P., Zhang Z., Kreiman J., Wilhalme H., Chhetri D.K.: Effects of Laryngeal Vibratory Asymmetry and Neuromuscular Compensation on Voice Quality.Laryngoscope., 2022; 132: 130\u2013134. doi: 10.1002\/lary.29724.","DOI":"10.1002\/lary.29724"},{"key":"634891r37","doi-asserted-by":"crossref","unstructured":"Gyawali C.P., Yadlapati R., Fass R. et al.: Updates to the modern diagnosisof GERD: Lyon consensus 2.0. Gut., 2024; 73: 361\u2013371. doi: 10.1136\/GUTJNL-2023-330616.","DOI":"10.1136\/gutjnl-2023-330616"},{"key":"634891r38","doi-asserted-by":"crossref","unstructured":"Koufman J.A.: Low-acid diet for recalcitrant laryngopharyngeal reflux: therapeutic benefits and their implications. Ann Otol Rhinol Laryngol., 2011; 120:281\u2013287. doi: 10.1177\/000348941112000501.","DOI":"10.1177\/000348941112000501"},{"key":"634891r39","doi-asserted-by":"crossref","unstructured":"Zalvan C.H., Hu S., Greenberg B., Geliebter J.: A Comparison of AlkalineWater and Mediterranean Diet vs Proton Pump Inhibition for Treatment ofLaryngopharyngeal Reflux. JAMA Otolaryngol Head Neck Surg., 2017; 143:1023\u20131029. doi: 10.1001\/JAMAOTO.2017.1454.","DOI":"10.1001\/jamaoto.2017.1454"},{"key":"634891r40","doi-asserted-by":"crossref","unstructured":"Park W., Hicks D.M., Khandwala F. et al.: Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapyand pretherapy predictors of response. Laryngoscope., 2005; 115: 1230\u20131238.doi: 10.1097\/01.MLG.0000163746.81766.45.","DOI":"10.1097\/01.MLG.0000163746.81766.45"},{"key":"634891r41","doi-asserted-by":"crossref","unstructured":"Lechien J.R.: Pharmacological and Biological Relevance in the Medical Treatment of Laryngopharyngeal Reflux: A State-of-the-Art Review. J Voice., 2024:1\u201316. Online ahead of print. doi: 10.1016\/j.jvoice.2024.11.014.","DOI":"10.1016\/j.jvoice.2024.11.014"},{"key":"634891r42","unstructured":"G\u0105siorowska A., Janiak M., Wa\u015bko-Czopnik D. et al.: Post\u0119powanie u pacjent\u00f3w z objawami choroby refluksowej prze\u0142yku \u2013 rekomendacje dla lekarzy rodzinnych. Lek POZ., 2019; 5: 245\u2013265."},{"key":"634891r43","doi-asserted-by":"crossref","unstructured":"Talley N.J., Tack J., Ptak T., Gupta R., Gigu\u00e8re M.: Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut., 2008; 57: 740\u2013746. doi: 10.1136\/GUT.2007.132449.","DOI":"10.1136\/gut.2007.132449"},{"key":"634891r44","doi-asserted-by":"crossref","unstructured":"Kim Y.S., Kim T.H., Choi C.S. et al.: Effect of itopride, a new prokinetic, in patientswith mild GERD: a pilot study. World J Gastroenterol., 2005; 11: 4210\u20134214.doi: 10.3748\/WJG.V11.I27.4210.","DOI":"10.3748\/wjg.v11.i27.4210"},{"key":"634891r45","doi-asserted-by":"crossref","unstructured":"Chun B.J., Lee D.S.: The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease. Eur Arch Otorhinolaryngol.,2013; 270: 1385\u20131390. doi: 10.1007\/S00405-012-2341-8.","DOI":"10.1007\/s00405-012-2341-8"},{"key":"634891r46","unstructured":"Ezzat W.F., Fawaz S.A., Fathey H., El Demerdash A.: Virtue of adding prokinetics to proton pump inhibitors in the treatment of laryngopharyngeal refluxdisease: Prospective study. J Otolaryngol Head Neck Surg., 2011; 40: 350. doi:10.2310\/7070.2011.100196."},{"key":"634891r47","doi-asserted-by":"crossref","unstructured":"Rohof W.O., Bennink R.J., Smout A.J.P.M., Thomas E., Boeckxstaens G.E.: Analginate-antacid formulation localizes to the acid pocket to reduce acid refluxin patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol.,2013; 11: 1585\u20131591. doi: 10.1016\/J.CGH.2013.04.046.","DOI":"10.1016\/j.cgh.2013.04.046"},{"key":"634891r48","doi-asserted-by":"crossref","unstructured":"De Ruigh A., Roman S., Chen J., Pandolfino J.E., Kahrilas P.J.: Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study. Aliment Pharmacol Ther., 2014; 40: 531\u2013537. doi:10.1111\/APT.12857.","DOI":"10.1111\/apt.12857"},{"key":"634891r49","doi-asserted-by":"crossref","unstructured":"Deraman M.A., Abdul Hafidz M.I., Lawenko R.M. et al.: Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacidin suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper. Aliment Pharmacol Ther., 2020; 51: 1014\u20131021.doi: 10.1111\/APT.15746.","DOI":"10.1111\/apt.15746"},{"key":"634891r50","doi-asserted-by":"crossref","unstructured":"Kwiatek M.A., Roman S., Fareeduddin A., Pandolfino J.E., Kahrilas P.J.: An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate ordisplace the postprandial \u201cacid pocket\u201d in symptomatic GERD patients. AlimentPharmacol Ther., 2011; 34: 59\u201366. doi: 10.1111\/J.1365-2036.2011.04678.X.","DOI":"10.1111\/j.1365-2036.2011.04678.x"},{"key":"634891r51","doi-asserted-by":"crossref","unstructured":"Cui N., Dai T., Liu Y. et al.: Laryngopharyngeal reflux disease: Updated examination of mechanisms, pathophysiology, treatment, and association withgastroesophageal reflux disease. World J Gastroenterol., 2024; 30: 2209\u20132219.doi: 10.3748\/wjg.v30.i16.2209.","DOI":"10.3748\/wjg.v30.i16.2209"},{"key":"634891r52","unstructured":"Palmieri B., Merighi A., Corbascio D. et al.: Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized doubleblind, placebo controlled study for the treatment of symptoms in patientswith non-erosive gastroesophageal reflux. https:\/\/www.europeanreview.org\/article\/6160 (11.11.2025)."},{"key":"634891r53","doi-asserted-by":"crossref","unstructured":"Savarino V., Pace F., Scarpignato C. et al.: Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease\u2013 efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther., 2017; 45: 631\u2013642. doi: 10.1111\/APT.13914.","DOI":"10.1111\/apt.13914"},{"key":"634891r54","doi-asserted-by":"crossref","unstructured":"Chmielecka-Rutkowska J., Tomasik B., Pietruszewska W.: The role of oral formulation of hyaluronic acid and chondroitin sulphate for the treatment of thepatients with laryngopharyngeal reflux. Otolaryngol Pol., 2019; 73: 38\u201349. doi:10.5604\/01.3001.0013.5776.","DOI":"10.5604\/01.3001.0013.5776"},{"key":"634891r55","doi-asserted-by":"crossref","unstructured":"Volpi N., Schiller J., Stern R., Soltes L.: Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem., 2009; 16: 1718\u20131745.doi: 10.2174\/092986709788186138.","DOI":"10.2174\/092986709788186138"},{"key":"634891r56","doi-asserted-by":"crossref","unstructured":"Sammarco G., Shalaby M., Elangovan S. et al.: Hyaluronan Accelerates Intestinal Mucosal Healing through Interaction with TSG-6. Cells., 2019, 8(9): 1074.doi: 10.3390\/CELLS8091074.","DOI":"10.3390\/cells8091074"},{"key":"634891r57","doi-asserted-by":"crossref","unstructured":"Komolafe K., Komolafe T.R., Crown O.O. et al.: Natural Products in theManagement of Gastroesophageal Reflux Disease: Mechanisms, Efficacy, and Future Directions. Nutrients., 2025, 17(6): 1069. doi: 10.3390\/NU17061069.","DOI":"10.3390\/nu17061069"},{"key":"634891r58","doi-asserted-by":"crossref","unstructured":"Lehner M.D., Scheyhing U., Els\u00e4sser J.: A combination of carbonates andOpuntia ficus-indica extract protects esophageal cells against simulated acidic and non-acidic reflux in vitro. Sci Rep., 2024, 14(1): 22355. doi: 10.1038\/S41598-024-74047-7.","DOI":"10.1038\/s41598-024-74047-7"},{"key":"634891r59","doi-asserted-by":"crossref","unstructured":"Pizzorni N., Ambrogi F., Eplite A. et al.: Magnesium alginate versus protonpump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial. Eur Arch Otorhinolaryngol., 2022; 279:2533\u20132542. doi: 10.1007\/S00405-021-07219-0.","DOI":"10.1007\/s00405-021-07219-0"},{"key":"634891r60","doi-asserted-by":"crossref","unstructured":"Patel A., Sayuk G.S., Gyawali C.P.: Parameters on esophageal pH-impedance monitoring that predict outcomes of patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol., 2015; 13: 884\u2013891. doi: 10.1016\/J.CGH.2014.08.029.","DOI":"10.1016\/j.cgh.2014.08.029"},{"key":"634891r61","doi-asserted-by":"crossref","unstructured":"Vaiciunaite D., Eriksson S.E., Sarici I.S. et al.: The Utility of Symptom Association Probability (SAP) in Predicting Outcome After Laparoscopic Fundoplication in Patients with Abnormal Esophageal Acid Exposure. J GastrointestSurg., 2023; 27: 2014\u20132022. doi: 10.1007\/s11605-023-05753-2.","DOI":"10.1007\/s11605-023-05753-2"}],"container-title":["Otolaryngologia Polska"],"original-title":[],"link":[{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0055.5225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0055.5225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:55:52Z","timestamp":1768204552000},"score":1,"resource":{"primary":{"URL":"https:\/\/otolaryngologypl.com\/gicid\/01.3001.0055.5225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,14]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0055.5225","relation":{},"ISSN":["0030-6657","2300-8423"],"issn-type":[{"value":"0030-6657","type":"print"},{"value":"2300-8423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]}}}